Drug intelligence / Profile preview

Lungvac

Development stage: Preclinical
Lead developer: Innovita Research
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intravenous

Overview

Lungvac is a preclinical-stage cell-based cancer vaccine being developed by Innovita Research for the treatment of lung cancer, specifically adenocarcinomas. As a cell therapy, it is designed to stimulate the patient's immune system to recognize and attack malignant cells associated with lung adenocarcinomas. The specific cellular components or antigens targeted by the vaccine have not been publicly disclosed by the sponsor.

Brand names: Lungvac
Other names: Lungvac

Beyond the preview

Go deeper on Lungvac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lungvac.

Explore the full profile